×

Schizophrenia breakthrough?

2:47 PM ET Wed, 7 Jan 2015

Shares of Alkermes are up nicely after positive data from its schizophrenia drug trial. Richard Pops, Alkermes CEO, provides insight to the enormous market for schizophrenia and depression.